Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Chemomab Therapeutics Ltd.ANCN · Entity 7653 | Director | April 23, 2020 | March 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Chemomab Therapeutics Ltd.
Report date April 23, 2020 · Filed March 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.17 · Expires 2030-07-15 | Direct | 55,000 |
Reported balance
After 2020-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-16 · Grant · Acquired 55,000 · Balance 55,000 F1: 25% of shares underlying the option vests on July 16, 2021, and 12.5% of the remaining shares underlying the option vest in eight equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of shares underlying the option vests on July 16, 2021, and 12.5% of the remaining shares underlying the option vest in eight equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2020 Filed Mar 12, 2021 21:28 UTC | Chemomab Therapeutics Ltd. ANCN · Entity 7653 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001209191-21-020164 · doc4.xml · derivative · entry 1 Polovets Stanislav · CIK 0001847625 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Ordinary Shares · 55,000 shares Expires 2030-07-15 F1 · derivative.exercise_date: 25% of shares underlying the option vests on July 16, 2021, and 12.5% of the remaining shares underlying the option vest in eight equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.